Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?-Reference-Cited by-同舟云学术

Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?

Published:2021-07 Issue:7 Volume:14 Page:e240078
ISSN:1757-790X
Container-title:BMJ Case Reports
language:en
Short-container-title:BMJ Case Rep

Author:

Carson Luke Nessan,Pradhan Ashish,Subramanian Deepak

Abstract

Omalizumab is an anti-IgE monoclonal antibody used in severe allergic asthma. Herein, we describe a case of eosinophilic granulomatosis with polyangiitis, which manifested 3 months after initiation of omalizumab therapy, while maintenance corticosteroid therapy dose was unchanged.

Publisher

BMJ

Subject

General Medicine

Reference18 articles.

1. The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)

2. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

3. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

4. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases;Celebi Sozener;World Allergy Organ J,2018

5. Omalizumab administration in Churg-Strauss syndrome;Giavina-Bianchi;Eur J Intern Med,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFETY OF OMALIZUMAB IN DIFFERENT PATIENT POPULATIONS;Bulletin "Biomedicine and sociology";2024-07-06

2. Safety of omalizumab in children;Glavvrač (Chief Medical Officer);2023-07-27

3. Risks and safety of biologics: A practical guide for allergists;World Allergy Organization Journal;2023-01

4. Safety of omalizumab in the treatment of moderate-to-severe bronchial asthma;Medical Journal of the Russian Federation;2022-07-26

5. Omalizumab/prednisolone/prednisone;Reactions Weekly;2021-08